

Nanotherapeutic modulation of excitotoxicity and oxidative stress in acute brain injury

Nanobiomedicine

Volume 7: 1–18

© The Author(s) 2020

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/1849543520970819

journals.sagepub.com/home/nabRick Liao¹, Thomas R Wood² and Elizabeth Nance^{1,3,4} 

Abstract

Excitotoxicity is a primary pathological process that occurs during stroke, traumatic brain injury (TBI), and global brain ischemia such as perinatal asphyxia. Excitotoxicity is triggered by an overabundance of excitatory neurotransmitters within the synapse, causing a detrimental cascade of excessive sodium and calcium influx, generation of reactive oxygen species, mitochondrial damage, and ultimately cell death. There are multiple potential points of intervention to combat excitotoxicity and downstream oxidative stress, yet there are currently no therapeutics clinically approved for this specific purpose. For a therapeutic to be effective against excitotoxicity, the therapeutic must accumulate at the disease site at the appropriate concentration at the right time. Nanotechnology can provide benefits for therapeutic delivery, including overcoming physiological obstacles such as the blood–brain barrier, protect cargo from degradation, and provide controlled release of a drug. This review evaluates the use of nano-based therapeutics to combat excitotoxicity in stroke, TBI, and hypoxia–ischemia with an emphasis on mitigating oxidative stress, and consideration of the path forward toward clinical translation.

Keywords

Stroke, TBI, hypoxia, ischemia, ROS, superoxide, glutamate, antioxidant, nanoparticles, clinical translation

Date received: 8 April 2020; accepted: 13 October 2020

The impacts and challenges of neurological disease

Acute brain injury is a common phenomenon associated with significant morbidity and mortality. Each year in the United States, around 800 thousand people suffer from a hemorrhagic or ischemic stroke, 60 thousand newborns experience perinatal asphyxia and subsequent hypoxia–ischemia (HI) encephalopathy, and three million people suffer from a traumatic brain injury (TBI).^{1–3} The costs associated with these diseases total over \$113 billion per year and are not limited to the medical treatments, subsequent pathological complications, and loss of earned wages throughout life; additional unquantifiable costs also include the physical and emotional toll on the individual, along with their caregivers, family, and friends.^{1,4,5}

Acute brain injuries exhibit a set of characteristic mechanisms that contribute to neurological damage. The pathological sequelae include immediate cell death and tissue loss followed by ongoing excitotoxicity, inflammation,

¹ Department of Chemical Engineering, University of Washington, Seattle, WA, USA

² Department of Pediatrics, Division of Neonatology, University of Washington, Seattle, WA, USA

³ Department of Radiology, University of Washington, Seattle, WA, USA

⁴ Center on Human Development and Disability, University of Washington, Seattle, WA, USA

Corresponding author:

Elizabeth Nance, Department of Chemical Engineering, University of Washington, 105 Benson Hall, Box 351750, Seattle WA, 98195, USA.
Email: eanance@uw.edu



and oxidative stress.^{6,7} Excitotoxicity is the pathological process of neuronal death due to dysregulated neuronal overstimulation by excitatory amino acids (EAAs) such as glutamate. Excitotoxicity leads to oxidative stress, where an excess of reactive oxygen species (ROS) exhausts native antioxidant systems. Understanding the etiology of neurological disease progression, especially the role of excitotoxicity and oxidative stress, is essential for determining ideal points of intervention for the development and implementation of effective therapeutics.

There have been extensive efforts in the fundamental sciences of pathology, immunology, and neuroscience to expand knowledge of excitotoxic neuronal death to elucidate key stages of intervention. Promising candidates include natural antioxidant, inorganic antioxidant-mimetic, and growth factor therapeutics, among others. However, developing a successful therapeutic requires a drug that not only has biochemical efficacy, but also effectively accumulates at the target site at therapeutic concentrations. In neurological disease, free drugs often fail to reach the target site due to *in vivo* degradation, systemic clearance mechanisms, and the barrier properties of the neurovascular unit.⁸ Consequently, despite the research progress achieved, there are currently no approved therapeutics for targeting excitotoxicity or its direct sequelae after acute neurological injury. Nanotechnology can be leveraged to help overcome each of the aforementioned delivery obstacles to the brain. By conjugating drugs to nanoparticle surfaces, encapsulating drugs within nanoparticles, or utilizing materials with intrinsic therapeutic effects in nanoparticle form, nanoparticle therapeutics can stabilize labile free drugs and traverse steric obstacles to reach diseased sites.⁸ Here, we provide an overview of the relevant disease mechanisms and points of intervention in excitotoxicity and subsequent oxidative stress including the advantages of nanotechnology, a summary of nanotherapeutic progress achieved thus far with a focus on *in vivo* work, and research strategies to implement for effective clinical translation.

Mechanisms of excitotoxicity in acute brain injury

Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS), responsible for the sense of sight, smell, taste (umami), nociception, and hearing, as well as the more complex processes of memory formation and learning.⁹ During neuronal activity, vesicles containing neurotransmitters in the presynaptic neuron merge with the membrane, expelling their contents, namely glutamate, into the synaptic cleft.¹⁰ Glutamate then rapidly diffuses across the synapse to bind to ionotropic glutamate receptors (iGluRs) on the postsynaptic neuron, eliciting an influx of sodium, which triggers an action potential that propagates down the neuron, forming the basis of neuronal communication.⁹ Astrocytic end feet enveloping the synapse rapidly

uptake glutamate to recycle back to the presynaptic neuron to replenish vesicular stores.¹¹ Upon neuronal excitation, calcium also influxes and binds to post synaptic density protein 95 (PSD-95) to initiate the recruitment of neuronal nitric oxide synthase (nNOS) and production of nitric oxide (NO).¹² NO then activates the nicotinamide adenine dinucleotide phosphate oxidase (NOX) complex that generates superoxide radical anion (SOX, O₂⁻).¹³

In acute brain injury, a number of pathological processes result in excitotoxicity depending on the nature of the insult. During stroke and HI, asphyxiation reduces ATP production leading to sodium/potassium ATPase pump failure and subsequent anoxic depolarization-induced glutamate release.¹⁴ Under hypoxia, as cells switch to lactic acid production and undergo acidosis, ATP generation further decreases, inhibiting ATP-dependent astrocytic glutamate uptake.¹⁵ In TBI, direct trauma induces immediate necrotic death of neurons and glia resulting in neuronal release of their glutamate stores, and subsequent dysregulation of cerebral blood flow leading to similar energy deficits as occurs in stroke and HI.^{16,17} Once blood flow returns after a hypoxic event, reperfusion injury may exacerbate neuronal damage.¹⁸ Regardless of the injury, excessive synaptic glutamate accumulation causes excitotoxicity.^{12,19} Substantially elevated intracellular glutamate, ROS, and calcium levels lead to cell death, increased glutamate release from dying neurons, and propagation of excitotoxicity.^{12,20}

Mitochondria play a prominent role in excitotoxicity, oxidative stress, and cell death processes due to energy, calcium, and ROS dynamics.²¹ During excitotoxicity, mitochondria uptake excess cytosolic calcium and produce high concentrations of SOX during mitochondrial respiration in response to excitatory postsynaptic currents.²² NOX-derived SOX triggers even greater SOX production from mitochondria.^{23–26} SOX mediates mitochondrial damage, resulting in electron transport chain failure as well as reverse electron transport leading to greater SOX production.²³ Other sources of SOX include production by xanthine oxidase or invading neutrophils during reperfusion, monoamine oxidase, and uncoupled nNOS by SOX oxidation of the nNOS cofactor tetrahydrobiopterin.^{18,27–30} Abundant SOX reacts with NO to form peroxynitrite, which can cause lipid peroxidation, protein deactivation, DNA mutation, and poly(ADP ribose) polymerase (PARP) activation.^{31,32} High intracellular calcium and SOX levels lead to extensive mitochondrial fission and mitochondrial permeability transition pore (mPTP) formation.^{22,33} The exact mechanism of mPTP formation remains to be elucidated, but ROS contributes several roles.^{34–36} mPTP formation results in burst release of SOX, calcium, and other necrosis and apoptosis effectors into the cytosol.³⁷ Mitochondrial burst release of SOX further induces NOX SOX production and neighboring mitochondrial stress, reducing mitochondrial antioxidant functions and creating a reinforcing cycle.^{23,38} As excitotoxicity, ROS generation, and

mPTP formation are intimately linked to death processes, ROS scavenging is a promising therapeutic strategy after acute brain injury.

After acute neurological injury, a number of neuroinflammatory processes occur both alongside and due to excitotoxicity. Oxidative stress plays a prominent role in neuroinflammation as well. SOX generated from NOX and subsequent oxidation to hydrogen peroxide (H_2O_2) elicit microglial proliferation and other downstream inflammatory signaling pathways.^{39,40} For instance, in perinatal asphyxia models, HI induces both excitotoxic neuronal death as well as neuroinflammatory microglial proliferation.⁴¹ Inflammation can in turn cause further delayed excitotoxicity, as occurs in depression and Parkinson's disease.^{42,43} Therefore, therapies that manage oxidative stress seen after acute neurological injury have the combined promise of alleviating excitotoxicity as well as neuroinflammation. An in-depth discussion of neuroinflammation is beyond the scope of this review, and we refer readers to other reviews.^{44–46} Figure 1 illustrates the major processes of excitotoxicity along with therapeutic points of intervention, while Table 1 introduces promising therapeutic candidates at these points of intervention and the potential benefits that nanotechnology can provide.

Therapeutic requirements for overcoming CNS barriers

To combat oxidative stress in excitotoxicity, a therapeutic must perform its biochemical function of scavenging ROS or inhibiting ROS generation but also be capable of reaching the diseased area. The mammalian body is highly efficient in the clearance of foreign substances. The kidneys readily filter out molecules smaller than 5–10 nm, while the liver metabolizes any molecule above 200 nm before reaching the brain.⁶⁹ Therapeutics also require an inert near-neutral surface charge to avoid non-specific adsorption to circulating serum proteins, extracellular matrix components, or cell membranes.⁷⁰ Without an inert surface, therapeutics can readily be opsonized for digestion by resident macrophages within many organs.⁷¹ Furthermore, the *in vivo* microenvironment may affect drug stability with potential deactivation due to proteases, oxidation/reduction, hydrolysis, pH, and unfavorable binding. Therapeutic proteins are especially susceptible to rapid degradation from *in vivo* proteases.^{72–74} Even after overcoming systemic clearance, a therapeutic must be capable of crossing the highly restrictive blood–brain barrier (BBB).⁷⁵ The BBB inhibits passage of all macromolecules such as proteins, and 98% of small molecule drugs.⁷⁶ However, in acute brain injuries such as stroke and TBI, there is some BBB breakdown, resulting in “leakiness” of the BBB to a wider range of molecules.^{77–79} We refer readers to other reviews that cover how acute brain injury mediates BBB breakdown.^{78,80} After admittance to the brain, a therapeutic must avoid expulsion by efflux transporters such as the P-glycoprotein, ATP-binding cassette, and solute carrier

transporters, and then subsequently navigate the brain parenchyma to reach diseased areas.^{81,82} Depending on the ultimate target, a therapeutic may also require a specific surface chemistry to undergo cell-type specific uptake.

Application of nanoparticles and their therapeutic benefits

Nanotechnology holds promise to both maintain therapeutic stability and overcome the barriers to brain delivery. There are a wide variety of nanoparticle platforms used for therapeutic delivery to the brain, including polymeric nanoparticles, liposomes, hydrogels, and dendrimers. Polymeric nanoparticles can provide controlled drug release, targeting capabilities, and prolonged drug action by protection from proteases, and have been shown to cross an intact or impaired BBB.^{72,83} Nanoparticle size, shape, flexibility, and surface charge can be tailored to overcome steric clearance and non-specific binding to alter pharmacokinetics and improve brain accumulation.^{84–86} With a dense poly(ethylene glycol) (PEG) coating, nanoparticles exhibit increased systemic circulation time by reducing interactions that lead to clearance and opsonization.⁷⁵ Densely-PEG coated nanoparticles up to 114 nm are also capable of diffusive and convective transport through the brain parenchyma.^{87,88} Drug-incorporation strategies include loading within nanoparticle matrices, cores, or lipophilic bilayers, or covalent conjugation to surface end groups.⁸ To improve pharmacokinetics or cellular uptake, nanoparticles can also be further decorated with surface ligands or surfactants, while incorporation of biology-responsive materials can further specialize therapeutic delivery.^{83,89} Incorporation of pH-sensitive groups can imbue nanoparticles with triggered release capabilities, only releasing drug when reaching the acidotic ischemic area, or when internalized within an acidic lysosome.^{90,91} Similar strategies apply for attachment of protease-cleavable linkers and oxidation/reduction-sensitive bonds.^{92,93} Superparamagnetic nanoparticles can also be guided to diseased tissue regions using magnetic resonance (MR).⁹⁴ Nanoparticles may also serve as biomarkers of disease, however, biomarker applications are outside the scope of this review and have been covered in other reviews.^{95,96} By leveraging the benefits of nanoparticle drug delivery and understanding neurological disease processes at the biomolecular level, therapeutic agents can be better designed to combat excitotoxicity.

ROS scavenging antioxidant enzyme-loaded nanoparticles

Nanoparticles have been investigated for delivering therapeutics in *in vivo* models of stroke, TBI, and HI. One of the most promising enzyme therapeutic candidates is superoxide dismutase (SOD), a native antioxidant enzyme that converts SOX into H_2O_2 and water. SOD-loaded polymeric poly(lactic-co-glycolic acid) (PLGA) nanoparticles reduced




Figure 1. Schematic overview of excitotoxic and oxidative stress processes in acute brain injury with points of intervention (white hexagons labeled A–G) at the A) synapse and B) mitochondria, where the left side is healthy, and the right side is injured. Excessive glutamate concentrations in the synapse can lead to excitotoxicity through enhanced ionotropic glutamate receptor activation, sodium and calcium influx, and generation of NO and SOX. These processes amplify mitochondrial ROS stress, resulting in mitochondrial fragmentation and mPTP formation, and release of calcium, SOX, and apoptotic cell death effectors.

infarct volume by 65% in a middle cerebral artery occlusion (MCAO) rat model, compared to only a 25% reduction from free SOD alone.⁹⁷ While 0% of rats survived without treatment after 4 weeks, SOD-nanoparticle application resulted in 75% survival.⁹⁸ Similarly, Yun et al. evaluated SOD delivery in liposomes, polybutylcyanoacrylate (PBCA) nanoparticles, and PLGA nanoparticles in a mouse model

of multi-vessel ischemia (MVI). All three platforms resulted in 35–45% infarct volume reduction, with 50–60% reduction when conjugated with N-methyl-D-aspartic acid receptor 1 (NMDA-R1) antibodies.⁹⁹ The efficacy of SOD-loaded liposomes against bilateral common carotid artery occlusion (BCCAO) was also evaluated in gerbils, where treatment prevented a decrease in endogenous SOD levels and

Table 1. Promising treatments for excitotoxicity in acute brain injury corresponding to Figure 1 points of intervention, labeled in white hexagons as A–G. These therapeutics could potentially benefit from nanoparticle strategies to surpass biological barriers and increase site specific localization.

Point of intervention	Therapeutic candidates	Mechanistic effect	Administration time after injury	Nanocarrier benefit
A Presynaptic glutamate release	levetiracetam ^{47,48}	Presynaptic glutamate release inhibitor	24 h, daily for 20 days ⁴⁷	Sustained release
B Ionotropic glutamate receptor	selfotel, aptiganel, eliprotil, licostinel, gavestinel ⁴⁹	N-methyl-D-aspartate (NMDA) receptor antagonist	Acute injury time window (within hours) ⁴⁹	Target site specific delivery
C Glutamate uptake	ceftriaxone ^{50–53}	Astrocytic EAAT2 expression upregulation	Within 24 h, daily for 4 days ⁵² , 30 m, daily for 7 days ⁵³	Target site specific delivery
D PSD-95	Tat-NR2B9C ^{54–56}	PSD-95 inhibitor	1 h ⁵⁴ ; 1 h or 3 h ⁵⁵ ; immediately ⁵⁶	Protease protection
E nNOS	2-iminobiotin ^{57–60}	iNOS and nNOS inhibitor	immediately ⁵⁸	Aqueous solubility
F SOX generation	allopurinol ^{61,62} apocynin ^{36,63,64}	Xanthine oxidase inhibitor NOX inhibitor	within 24h ⁶¹ ; 15m ⁶² 15 m prior ⁶³ ; 30 m prior ⁶⁴	Controlled release Target site specific delivery
G Mitochondrial metabolism	creatine ^{65–67} nicotinamide riboside ⁶⁸	Improve mitochondrial bioenergetics Precursor for NAD ⁺ , improve mitochondrial bioenergetics	Acute injury time window (within hours) ⁶⁵ Immediately ⁶⁸	BBB permeability Target site specific delivery

*denotes analysis based on clinical patients.

mitigated mitochondrial membrane lipid peroxidation but failed to reduce brain swelling.¹⁰⁰ From other studies, SOD-loaded liposomes reduced infarct size by 18–33% after focal cerebral ischemia in rats, and reduced BBB permeability and brain edema in cold-induced TBI rats.^{101,102} In a MCAO mouse model, SOD-encapsulating polyion condensation complexes of PEG-b-poly(L-lysine) (PEG-PLL) or PEG-b-poly(aspartate diethyltriamine) (PEG-DET) followed by crosslinking reduced infarct volume by 50–60%.^{103,104}

Even though SOD converts SOX into H₂O₂, there is evidently a therapeutic benefit in reducing SOX levels at the expense of increasing H₂O₂ levels, by reducing mitochondrial oxidative stress and fragmentation.¹⁰⁵ Catalase scavenging of H₂O₂ by itself or in tandem with SOX scavenging has also shown positive effects in reducing acute brain injury. Catalase delivery via PLGA polymer or polyion complexed micelle nanoparticles has been explored *in vitro*, but *in vivo* application has been limited.^{106,107} Zhang et al. observed a reduction in infarct size with cross-linked dendrigraft poly-L-lysine (DGL) nanoparticles containing cis-aconitic anhydride-modified catalase after MCAO in mice, with further infarct reduction when nanoparticles were decorated with N-acetyl-proline-glycine-proline tripeptides with a high affinity for neutrophils, which enhanced BBB penetration.¹⁰⁸ SOD and catalase loaded separately into PLGA nanoparticles were administered after tissue plasminogen activator (tPA) in a thromboembolic stroke rat model, resulting in reduced number of caspase-positive cells, neutrophils, and hippocampal swelling, and an increase in nestin-positive neuron progenitor cells.¹⁰⁹ Combinatorial delivery of SOD nanoparticles and catalase nanoparticles offers promise in disrupting neuronal death processes via interruption of SOX-mediated primary damage as well as longer time-scale inflammatory processes caused by H₂O₂ accumulation.¹¹⁰ Although enzyme-encapsulating nanoparticles are promising for combating excitotoxicity with their precise and continuous catalytic functions, enzyme delivery still faces many challenges including poor hydrophilic macromolecule loading in hydrophobic matrices, and enzyme deactivation from high-energy mixing and organic/aqueous interfaces during formulation processes.^{111–114} Researchers are exploring other antioxidant-capable nanoparticle strategies that circumvent some of these challenges.

ROS scavenging antioxidant-mimetic materials as nanoparticles

Nanoparticles themselves may be composed of therapeutic materials that exhibit antioxidant capabilities.^{115,116} Cerium oxide nanoparticles of 4 nm diameter exhibit SOD- and catalase-mimetic activity, and can scavenge NO, and peroxynitrite.¹¹⁷ They have been shown to reduce infarct size by over 50% after MCAO in rats at 0.5 mg/kg and 0.7 mg/kg doses.¹¹⁸ Interestingly, higher concentrations

of 1 mg/kg and 1.5 mg/kg provided no significant change in infarct volume compared to no treatment.¹¹⁸ Capping cerium oxide nanoparticles with zeolitic imidazolate framework-8 further improved ROS scavenging ability.¹¹⁹ Cerium oxide nanoparticles have been covered in-depth in other reviews.^{117,120,121} Platinum nanoparticles are also SOD- and catalase-mimetics and result in reduced infarct size in the cortex after transient MCAO in mice.¹¹⁶ Yttrium oxide nanoparticles have similar antioxidant effects as cerium oxide nanoparticles in *in vitro* cell culture and could warrant further exploration.¹²²

Fullerene nanoparticles, which are carbon allotropes consisting of 60 carbons in a spherical arrangement, have also been investigated for their free radical scavenging capabilities of neutralizing hydroxyl radicals, SOX, and NO by transferring radicals into stable conformations within the fullerene nanoparticle.^{123–125} Hydroxylated fullerene nanoparticles reduced neuronal death in the CA1 hippocampal region after MVI in rats.¹²⁶ Vani et al. applied hydroxylated fullerene nanoparticles before or after MCAO in rats, yielding a 53% or 81% reduction in infarct volume, respectively, a reduction in malondialdehyde levels, and rescuing of reduced glutathione (GSH) content and SOD activity.¹²⁷ Carboxyfullerene nanoparticles decreased cortical infarction and prevented GSH depletion and lipid peroxidation, but also had adverse effects including writhing and even death in rats after MCAO and BCCAO.¹²⁴ Fullerenes can also produce pro-oxidant SOX and singlet oxygen in the presence of UV light, which could lead to adverse effects if fullerene nanoparticles localize in skin epithelium.¹²⁵ This UV-induced radical producing capability warrants further study of fullerene nanoparticles in the presence of other biologically relevant radical-generating conditions such as free iron.

PEG-functionalized hydrophilic carbon clusters (PEG-HCCs) consisting of 40 nm by 2–3 nm carbon nanotubes have also been explored for excitotoxic and immunomodulation applications due to their SOD-mimetic and hydroxyl radical scavenging properties.^{128,129} Interestingly, PEG-HCCs are inert towards NO and peroxynitrite, holding potential as selective ROS scavengers that avoid NO scavenging and consequent vasodilatation and blood flow interference.¹²⁸ PEG-HCCs can also load hydrophobic molecules into their hydrophobic core for combinatorial therapy.¹³⁰ PEG-HCCs administered during reperfusion of transient MCAO rats under hyperglycemic conditions resulted in a 42% reduction in infarct size, and reduced edema and hemorrhage.¹³¹ PEG-HCCs furthermore normalized NO and SOX levels and restored cerebral blood flow after controlled cortical impact (CCI)-induced TBI in rats.¹³² With self-regenerating ROS-specific rapid antioxidant capacity, PEG-HCCs warrant further investigation as a viable excitotoxicity therapeutic for stroke and TBI applications.¹³⁰ Due to the non-biological origin of antioxidant-mimetic material nanoparticles and their relatively recent application in the neurological disease fields, further

research is also needed to assess their long-term biocompatibility, clearance and pharmacokinetics, and maximum tolerated dosing before translation to clinical trials can be achieved.^{133,134}

Broad-acting antioxidant-loaded nanoparticles

While the antioxidant-nanoparticle strategies covered thus far have focused on specific scavenging of SOX and/or H₂O₂, there are also several broad-acting antioxidants that have utilized nanoparticle delivery to improve therapeutic accumulation at the target site to enhance efficacy. Erythropoietin (EPO) exerts its neuroprotective effects for acute brain injury by chelating iron to reduce radical formation, modulating inflammation in multiple brain cell types, and acting as a neurotrophic agent.^{135–137} EPO delivery within PLGA nanoparticles has been shown to reduce infarct volume in a perinatal rat model of HI at 10 times lower doses than recombinant EPO.¹³⁸

Curcumin is a small molecule found in the culinary spice turmeric that has broad-acting anti-inflammatory and antioxidant effects. Curcumin has been associated with activation of the antioxidant response element pathway in mice after closed-skull impact-induced TBI, ~50% infarct volume reduction after MCAO in rats, and microglial polarization towards the anti-inflammatory state after distal MCAO in mice.^{139–141} However, curcumin's direct application for acute brain injury is suboptimal due to its hydrophobicity and consequent low aqueous solubility. Curcumin incorporation within PLGA-PEG nanoparticles permitted curcumin penetration across the BBB, diffusion effectively to disease sites, and a decreased infarct size in neonatal HI rats while free curcumin provided no significant therapeutic efficacy.⁴¹ Curcumin-loaded within solid lipid nanoparticles administered orally to rats after BCCAO also improved neurological scoring by 79% and restored SOD, GSH, and catalase levels to sham control levels.¹⁴² Curcumin-loaded N-isopropyl acrylamide (PNIPAM) nanoparticles administered intranasally after MCAO in rats restored grip strength, locomotor activity, glutathione peroxidase, glutathione reductase, SOD, and catalase activity, and reduced lipid peroxidation and neuronal loss by ~40%.¹⁴³

Multiple other antioxidants have also shown promise for acute brain injury when incorporated into nanoparticle platforms. Melanin exhibits broad antioxidant activity against SOX, H₂O₂, hydroxyl radical, peroxynitrite, and NO.¹⁴⁴ Injection of PEGylated melanin nanoparticles before MCAO injury in rats resulted in ~50% infarct reduction and showed no immediate toxicity in preliminary *in vitro* and *in vivo* studies.¹⁴⁴ N-acetylcysteine (NAC) is a precursor to GSH and therefore an antioxidant and free radical scavenger, as well as a pleiotropic anti-inflammatory agent.¹⁴⁵ Once internalized into cells, NAC is hydrolyzed to release cysteine which is then used for GSH production.¹⁴⁵ NAC-conjugated dendrimers (D-NAC) administered to neonatal mice that underwent

permanent unilateral carotid artery ligation with mild hypoxia improved white matter myelination.¹⁴⁶ Adenosine provides neuroprotection by binding to inhibitory adenosine A₁ receptors to hyperpolarize neurons and reduce glutamate release, mitigating downstream excitotoxic processes.^{147,148} The hydrophilic small molecule adenosine is readily metabolized and cleared in the bloodstream, but when conjugated to squalene and formed into nanoparticles, these adenosine complexes significantly improved neurologic deficit scores after MCAO in mice.¹⁴⁹ The natural polyphenol antioxidant resveratrol is water insoluble with a short half-life in its free form.¹⁵⁰ Resveratrol-loaded poly(N-vinylpyrrolidone)-b-poly(ϵ -caprolactone) (PVP-b-PCL) polymeric nanoparticles reduced infarct volume by 30–40%, malondialdehyde levels, and neuronal apoptosis after transient MCAO in rats.¹⁵⁰ The flavanone glycoside antioxidant hesperidin suffers from poor BBB passage and therefore bioavailability.¹⁵¹ Hesperidin nanoparticles increased GSH, catalase, and total protein levels, and decreased infarct volume and malondialdehyde levels after BCCAO in rats.¹⁵¹ Broad-acting antioxidants are promising in mitigating ROS damage in acute brain injury, and many also exhibit broad anti-inflammatory properties as well, which may further improve therapeutic efficacy. However, because pleiotropic drugs act via multiple neuroprotective mechanisms, gaining broader understanding of which specific mechanisms to target from these studies to combat excitotoxicity is limited.

Our review of anti-excitotoxicity and antioxidant therapeutic efficacy has focused on survival, infarct volume reduction, and oxidative stress markers at the molecular and cellular scales. Fortunately, physical improvement overall correlated well with behavioral outcomes across antioxidant-nanoparticle studies.^{98,116,131,138,142} For example, infarct reduction occurred alongside improvements in hind limb flexion, the ability to walk straight, and noise sensitivity upon administration of SOD-loaded PLGA nanoparticles after transient MCAO in rats.⁹⁸ However, slight impairment in forelimb movement and blinking reaction remained.⁹⁸ Platinum nanoparticles and PEG-HCCs improved performance on the Bederson exam, encompassing forelimb strength, stability from pushing, and circling behavior, alongside infarct reduction after transient MCAO in rats.^{116,131} Nanoerythropoietin in a neonatal HI rat model, platinum nanoparticles after MCAO in rats, and curcumin-loaded solid lipid nanoparticles after BCCAO in rats improved performance on the Rotarod test alongside infarct reduction.^{116,138,142} Curcumin-loaded solid lipid nanoparticles also improved Morris water maze and elevated plus maze performance to closer to that of sham injury scores.¹⁴²

Pitfalls of translating anti-excitotoxic therapies

There remains a distinct lack of therapeutics targeting excitotoxicity in routine clinical use, despite having been described as a key component of the pathophysiology of

acute neurological injury mechanisms for several decades. A large part of this lack of successful translation is likely due to the issues outlined above—the requirement of more targeted or stable delivery of therapeutics to the site of injury. However, a number of other obstacles or common problems exist in the translational pipeline that should be addressed as new therapeutics are developed. These include the timing of the therapeutic, adequate control of confounding physiological factors in preclinical studies, and the number and heterogeneity of animal models assessed before moving to clinical trials.

The timing of therapies with respect to the specific pathophysiological processes that occur after injury is a crucial component of successful clinical translation. This is likely to be particularly important for therapies that directly target the accumulation of EAAs such as glutamate. For instance, in piglet models of perinatal HI brain injury, a small increase in extracellular glutamate is seen during the insult itself as a result of primary energy failure, followed by a decrease after resuscitation until a significant increase as secondary energy failure occurs 6–12 h later.¹⁵² Preclinically, therapeutic hypothermia (TH) is significantly neuroprotective in a wide range of acute brain injuries, at least in part due to its ability to suppress the release of EAAs.^{153–155} However, TH has only shown clinical success after perinatal asphyxia, and must be initiated within 6 h of the injury or earlier for maximum benefit.¹⁵⁶

Similarly, the NMDA-R antagonist xenon augments hypothermic neuroprotection in rat and piglet models of perinatal asphyxia when given at a concentration of 50% and initiated within 3 h of resuscitation.^{157–159} Yet, the TOBY-Xe trial found no benefit of adding xenon to TH for infants after birth asphyxia, with significant confounders including that median time of xenon onset was 10 h (range: 4.0–12.6 h), and that it was given at a concentration of 30%.¹⁶⁰ Overall, the data therefore suggest that any directly anti-excitotoxic therapy must be in place as soon as possible after reperfusion.¹⁵⁶ This may be because of ongoing excitotoxicity that occurs even in the absence of measurable increases in extracellular glutamate. For instance, despite the relatively delayed rise in glutamate after injury, others have shown that an “excitotoxic index” consisting of relative levels of glutamate, aspartate, and glycine to γ -aminobutyric acid (GABA) begins to increase almost immediately after resuscitation in a piglet model of perinatal HI brain injury.¹⁶¹ In the clinical setting, it is likely that any anti-excitotoxic therapeutic should therefore be at high local concentrations within 3–6 h of the initial injury, and this must be incorporated into the design of both preclinical and clinical studies. Importantly, therapies that target downstream mitochondrial dysfunction, neuroinflammation, oxidative stress, and delayed neurodegeneration, which continue to occur over hours to days, may have an extended therapeutic window as long as they can be reliably delivered to the site of injury.^{162,163}

The history of anti-excitotoxic therapies, particularly when used in rodent studies, is significantly confounded by issues with temperature regulation because hypothermia, which is known to be neuroprotective, spontaneously occurs after brain injury and is rarely adequately controlled.^{156,164–166} Additionally, glutamate signaling plays a dominant role in thermoregulation and maintenance of normal temperature, with pharmaceutical inhibition of glutamate signaling generally associated with loss of cold-evoked temperature responses (e.g. brown fat thermogenesis), and subsequent hypothermia.^{167–169} In both animal models and humans, early spontaneous hypothermia is a common occurrence after global brain injury, with greater decreases in core temperature generally seen with a greater extent and severity of injury.^{166,170–173} In preclinical models at least, this spontaneous hypothermia can result in neuroprotection, with enforced periods of temperature regulation required after injury to standardize the degree of injury seen.^{166,174} However, in one analysis of studies assessing neuroprotective strategies in adult rodent models of both global and focal ischemia, only around 30% of studies did temperature measurements after the injury procedure.¹⁶⁴ A more recent analysis of preclinical studies examining neuroprotective agents in perinatal HI injury found similar results.¹⁶⁵

In their seminal paper in 2006, O'Collins et al. described "1,026 Experimental Treatments in Acute Stroke," the vast majority of which had not been translated to clinical trials.¹⁷⁵ Anti-excitotoxic therapies provided, on average, about 25% neuroprotection, which was a similar magnitude to thrombolysis, the current standard of care for acute ischemic stroke. The general lack of successful translation of anti-excitotoxic therapies in this setting may either be due to problems with timing relative to injury, or that the majority of benefit from directly anti-excitotoxic therapies, for instance those that regulate glutamate release or signaling, result in hypothermia that is not controlled for in the preclinical setting.^{164,165} Hypothermia has not been shown to be robustly beneficial after stroke, TBI, or global brain ischemia (e.g. after cardiac arrest) in pediatric or adult populations.^{153,155,173} However, rigorous temperature management is commonplace in hospitalized adults after global and focal acute brain injuries due to the benefit of preventing hyperthermia (fever).^{153,173,176,177} Therefore, more evidence is still required to examine whether directly anti-excitotoxic therapies will have their place in routine clinical use by providing neuroprotection above and beyond their effects on thermoregulation. Although promising, antioxidant-nanoparticle therapies will also necessarily undergo the same rigor of evaluation before clinical translation.

Barriers to clinical translation of nanotechnologies for acute brain injury

As with the majority of putative therapies developed for treating neurological disorders, any lack of success in the

clinical setting could potentially be determined earlier by developing an adequate preclinical pipeline.¹⁷⁸ This was the goal of the STAIR (Stroke Therapy Academic Industry Roundtable) criteria when they were developed more than two decades ago. To fully meet the criteria, a therapy had to be successfully tested: i) in two or more laboratories, ii) in two or more species, iii) in animals at a disease-appropriate life stage, iv) in both sexes, v) in both temporary and permanent models of ischemia, vi) at least 1 hour after reperfusion, vii) at two or more doses, viii) using a clinically relevant mode of delivery, ix) using both histological and behavioral outcomes, and x) with outcomes at least 4 weeks after injury. Unfortunately, these criteria, as well as the ARRIVE (Animal Research: Reporting of *In Vivo* Experiments) criteria for design and reporting of preclinical studies, are still rarely applied today.¹⁷⁸

In addition to these criteria, any use of nanotechnology to transport therapeutic cargo must also include the necessary controls to account for the nanoparticle vehicle and any component of the nanoparticle that could result in toxicity, off-site effects, or added therapeutic benefit. For nanoparticles encapsulating a therapeutic, this typically involves adding treatment groups for the empty nanoparticle and the free drug. For therapeutics chemically linked to nanoparticles, controls might also need to include the nanoparticle with and without the linker chemistry. Further complicating preclinical studies, the use of nanoparticles to deliver therapeutics should decrease the necessary dose of the therapeutic; yet, this difference in dose between the therapeutic nanoparticle and the therapeutic in free form introduces an additional variable. Inevitably, the more multifunctional the nanoparticle delivery system, the more controls are needed to account for the potential effects of each component of that system.

While nanotechnologies might increase drug bioavailability and reduce dosing needs over the longer term, initial preclinical studies often require more experimental groups. Meeting these needs increases costs substantially, especially when scaling nanotherapeutic formulation methods to test in multiple animal models with increasingly larger species. By not testing therapies in multiple animal models, including both rodent species and larger gyrencephalic animals (pigs, sheep, dogs, nonhuman primates, etc.) at multiple different time points in relation to the initial injury, the preclinical pipeline is unlikely to capture the heterogeneity of acute brain injury populations seen clinically. Preclinical work often focuses on reproducibility of injury to maintain statistical power while using small group sizes, and without testing a therapy in the variety of settings outlined in the STAIR criteria, the likelihood of failure in the clinic will remain high.¹⁷⁸ Any anti-excitotoxicity therapy must achieve target site delivery at the right dose at the right timing of injury. Therefore, a robust preclinical pipeline including a combination of complementary models (Table 2) is paramount in the translation of nanotherapeutics for the treatment of excitotoxicity and oxidative stress.

Table 2. *In vitro* and *in vivo* models of excitotoxicity, stroke, TBI, and HI. For each model, the method in which the injury was created, the species that have been tested, the brain macrostructure (lissencephalic or gyrencephalic), the injury type, and the pros and cons of the model have been specified to enable identification of complementary multi-species models to evaluate promising therapeutics. Abbreviations: AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BCCAO, bilateral common carotid artery occlusion; CCI, controlled cortical impact; CHIMERA, Closed-head impact model of engineered rotational acceleration; ICP, intracranial pressure; LPS, lipopolysaccharide; MCAO, middle cerebral artery occlusion; OGD, oxygen-glucose deprivation; Poly(I: C), polyinosinic: polycytidylic acid; TBI, traumatic brain injury; TLR, Toll-like receptor.

Setting	Target disease	Model	Species	Brain type	Injury type	Pros	Cons
<i>In vitro</i>	Hypoxia-ischemia (general)	OGD	Rodents (rats, mice)	Organotypic brain slices	Global (whole brain/hemisphere slice) Focal (region-specific e.g. hippocampus)	Amenable to a wide range of biochemical assessments; Can perform electrophysiology and live cell imaging of subcortical structures; Fewer animals required for initial screening of therapies; Can maintain many cytoarchitectural features of the intact brain; Inflammatory stimuli can be added to media to target TLR4 (e.g. LPS), TLR3 (e.g. Poly(I: C)), and TLR1/2 (e.g. PAM3CSK4)	Specific culturing conditions affect slice stability and outcome assessments; Correlates with long-term or behavioral outcomes not possible
	Excitotoxicity (general)	Specific excitotoxins e.g.: NMDA Kainate MSG AMPA Traumatic slice culture injury	Rodents (rats, mice)		Global (whole brain/hemisphere slice) Focal (region-specific e.g. hippocampus)		
<i>In vivo</i>	TBI	CCI	Rodents (rats, mice) Ferrets Pigs Nonhuman primates Sheep Rabbits	Lissencephalic Gyrencephalic	Global (e.g. rolled weight) Focal (e.g. targeted impact) Focal	Controlled impact reduces variability in injury between animals; Different cortical areas can be targeted in larger animals; Ferret model allows for long-term assessments in gyrencephalic brain	Long-term outcomes limited in large animal models; Requires craniotomy; Focal injury is not representative of most closed-skull TBIs; Not amenable to repeat injuries; Ferret behavioral deficits may decrease over time
	TBI	Fluid percussion	Rodents (rats, mice) Cats Dogs Sheep Rabbits	Lissencephalic Gyrencephalic	Focal/Global	Controlled impact reduces variability in injury between animals; Different cortical areas can be targeted in larger animals; Fluid impact can reproduce effects of shearing stress; Recapitulates some aspects of systemic physiological changes after TBI	Long-term outcomes limited in large animal models; Requires craniotomy; Exogenous fluid in the skull cavity interferes with assessment of edema/ICP; Focal necrosis at site of impact is not representative of most closed-skull TBIs
		Closed-skull impact (small animal)	Rodents (rats, mice)	Lissencephalic	Global	Etiology similar to many clinical TBIs (direct impact); Rodents are amenable to wide range of short- and long-term outcome assessments	High risk of skull fracture; May not replicate the axonal and white matter injuries seen clinically; High inter-animal and inter-laboratory variability
		Acceleration injury (large animal)	Sheep Pigs Nonhuman primates	Lissencephalic	Global	Etiology similar to many clinical TBIs (direct impact with rotational component); Gyrencephalic animals better replicate axonal and white matter injuries; Amenable to assessing systemic physiological and cerebrovascular/ICP changes	Long-term outcomes limited in large animal models; Antibody-based biochemical assessments more limited in large animals
	Blast injury		Rodents (rats, mice) Ferrets Rabbits Dogs Pigs Rodents (rats, mice) Ferrets	Lissencephalic Gyrencephalic	Global	Accurately replicates blast-style injuries including lung pathology and systemic inflammatory responses; Ferret model allows for long-term assessments in gyrencephalic brain	Requires significant technical expertise and equipment; Less relevant model for non-blast TBIs
	CHIMERA		Rodents (rats, mice) Ferrets	Lissencephalic Gyrencephalic	Global	Provides ability to standardize impacts in small animals across laboratories; Etiology similar to many clinical TBIs (direct impact with rotational component); Allows for multiple exposures; Amenable to a wide range of short- and long-term outcome assessments; Ferret model allows for long-term assessments in gyrencephalic brain	High risk of skull fracture with higher impact energies or repeat exposures; Less well validated compared to more-established TBI methodologies; Ferret model has not been reproduced in multiple labs

(continued)

Table 2. (continued)

Setting	Target disease	Model	Species	Brain type	Injury type	Pros	Cons
Stroke	MCAO	Rodent (rats, mice)	Lissencephalic	Focal	Can model both permanent and transient ischemia; Replicates major vessel occlusions seen clinically; Amenable to a wide range of short- and long-term outcome assessments; Well-validated histopathological and behavioral outcomes; Unaffected contralateral hemisphere can act as internal control for certain assessments	Must be performed in aged/diseased animals to ensure clinical relevance; Significant intra-operator variability in injury	
	Photocoagulation or thrombosis	Rodents (rats, mice)	Lissencephalic	Focal	Models microvascular ischemia without altering surrounding tissue; Replicates effects of micro-infarcts; Can be used to examine effects in highly-circumscribed areas	Does not model large vessel stroke; Typically restricted to the peripheral cortex; Does not result in behavioral deficits	
	Multi-vessel ischemia	Rats	Lissencephalic	Focal	Models transient global ischemia (+/- permanent vessel occlusion); Amenable to a wide range of short- and long-term outcome assessments;	Must be performed in aged/diseased animals to ensure clinical relevance; Technically more challenging than focal stroke models	
	BCCAO	Rodents (rats, mice)	Lissencephalic	Global	Well-validated histopathological and behavioral outcomes; Models transient global ischemia; Amenable to a wide range of short- and long-term outcome assessments;	Must be performed in aged/diseased animals to ensure clinical relevance	
Neonatal HI/stroke	MCAO	Rodents (rats, mice)	Lissencephalic	Focal	Well-validated histopathological and behavioral outcomes; Replicates major vessel occlusions seen clinically; Amenable to a wide range of short- and long-term outcome assessments;	Must be used in age-appropriate animals to model neonatal stroke; Significant intra-operator variability in injury	
	Unilateral hypoxia-ischemia (e.g. "Yannucci model")	Rodents (rats, mice)	Lissencephalic	Global (hemisphere)	Well-validated histopathological and behavioral outcomes; Unaffected contralateral hemisphere can act as internal control for certain assessments;	Injury pattern does not accurately replicate HI pathology; High degree of intra-laboratory and inter-laboratory variability	
	BCCAO	Ferrets Piglets Fetal sheep	Gyrencephalic	Global	Can model inflammatory exposures via TLR4 (e.g. LPS), TLR3 (e.g. Poly(I: C)), and TLR1/2 (e.g. PAM3CSK4) Gyrencephalic models more accurately model clinical pathologies; Large animals are amenable to more clinically relevant (several day) treatment times; Large animals support a range of clinically relevant physiological monitoring; Can model inflammatory exposures via TLR4 (e.g. LPS), TLR3 (e.g. Poly I: C), and TLR1/2 (e.g. PAM3CSK4); Can model systemic illness if model incorporates systemic hypoxia/hypotension; Ferret and sheep models can be used to model multiple term/ preterm equivalent ages	Ferret model currently less well validated compared to others; Ferret model has not been reproduced in multiple labs; Long-term outcomes limited in large animals (piglets, fetal sheep); Often limited by outcomes after 18–24 h; Multi-day experiments in piglets require significant technical and personnel expertise	
	Umbilical cord occlusion	Nonhuman primates Fetal sheep	Gyrencephalic	Global	Gyrencephalic models more accurately model clinical pathologies; Large animals are amenable to more clinically relevant (several day) treatment times; Large animals support a range of clinically relevant physiological monitoring; Can model inflammatory exposures via TLR4 (e.g. LPS), TLR3 (e.g. Poly I: C), and TLR1/2 (e.g. PAM3CSK4); Primate models are amenable to long-term technical imaging and behavioral assessments	Term primate model developmentally older than term human; Experiments in primates require significant technical and personnel expertise; Long-term outcomes limited in fetal sheep	

(continued)

Table 2. (continued)

Setting	Target disease	Model	Species	Brain type	Injury type	Pros	Cons
	Cerebral Palsy	Intrauterine hypoxia	Rabbits Rodents (rat, mouse)	Lissencephalic	Global	Intrauterine LPS may be administered before/during hypoxia period to increase injury; Rodent model mimics early-life intra-uterine exposures/premature brain injury; Rodent model amenable to a wide range of short- and long-term outcome assessments; Rabbit model mimics a motor phenotype similar to cerebral palsy (not seen in rodent models)	Rabbit model not fully characterized with respect to pathological outcomes; Rodent behavioral deficits may decrease over time; High degree of mortality; Lissencephalic animals poorly model white matter injury seen in preterm infants; Rabbit model has not been reproduced in multiple labs
		Intrauterine inflammation	Rabbits	Lissencephalic	Global	Largely inflammatory model; Intrauterine LPS administration as main injury stimulus; Mimics a motor phenotype similar to cerebral palsy (not seen in rodent models)	White matter focused injury so does not capture pathological changes in gray matter; Model has not been reproduced in multiple labs
	Cardiac Arrest	Cardiac arrest/resuscitation	Rodents (rats, mice) Dogs Pigs Nonhuman primates	Lissencephalic Gyrencephalic	Global	Clinically relevant global injury model; Gyrencephalic models more accurately model clinical pathologies; Large animals are amenable to more clinically relevant (several day) treatment times; Large animals support a range of clinically relevant physiological monitoring; Rodent model amenable to a wide range of short- and long-term outcome assessments	Resuscitation can be technically challenging; Long-term outcomes limited in large animal models; Must be performed in appropriately aged/diseased animals to ensure clinical relevance
	Excitotoxicity (general)	Intracranial excitotoxin injection, for example: Kainate AMPA Ibotenate	Rodents (rats, mice)	Lissencephalic	Global (systemic) Focal (intracerebral)	Allows for mechanistic evaluation of excitotoxic pathophysiology; Can either be global (e.g. kainate-induced seizures) or focal (e.g. intracerebral ibotenate) injury; Amenable to a wide range of short- and long-term outcome assessments	Does not capture the wide-ranging pathological mechanisms encountered clinically

Conclusions and looking forward

Delivering drugs that act specifically at diseased target sites at the appropriate dose at the right time is crucial for neurotherapeutics given the sensitivity and precision of brain function. Antioxidant intervention by scavenging injury-associated SOX and other ROS provides alleviation of multiple subsequent neuronal death pathways. Many studies have already shown the therapeutic potential of SOD-loaded nanoparticles or SOD-mimetic platforms, as well as various other antioxidants. However, despite promising inhibition of excitotoxic damage, further work needs to be performed to identify the ideal intervention point for therapeutic efficacy.

Understanding the mechanisms involved in excitotoxicity and oxidative stress can assist the nanoparticle drug delivery field in identifying promising points of intervention. Therapeutic development to inhibit ROS production can be guided by pinpointing the threshold at which ROS overwhelms antioxidant defenses and whether antioxidant uptake would enhance therapeutic effect. Determining whether excessive SOX elevation is primarily generated by NOX after glutamate receptor activation, by respiring mitochondria, or by xanthine oxidase after reperfusion, or whether the SOX source even matters, would better inform how to target the downstream pathology. However, it is imperative to remember that excitotoxicity is not the only disease hallmark at play. Inhibition of ROS in neuroinflammatory pathways could also assist in preventing delayed neurodegeneration that can arise days, months, or even years later.^{163,179} Since neuronal excitation and inflammation play roles in survival and growth, there is risk of injuriously over-inhibiting basal neuronal function or over-scavenging ROS and interrupting cell signaling.^{40,179–181}

Preclinically, most antioxidant-nanoparticle therapies achieved no greater than 60% reduction in infarct size on ischemia/reperfusion, HI, or TBI injury *in vivo*. It remains to be elucidated whether ~60% reduction is a practical limit, or whether additional strategies could further reduce damage. Therapeutic advances achieving greater than 60% infarct reduction could consist of increasing drug concentrations at injured sites, using targeting ligands for improved accumulation or cell-specific uptake at the target site, optimization of the timing of administration, or applying combination therapies with anti-inflammatory agents, pro-regenerative growth factors, or stem-cell based therapies. Furthermore, despite extensive preclinical evidence of antioxidant-nanoparticle efficacy in acute brain injury, research must comply with STAIR and ARRIVE criteria before translation to clinical studies. Finally, though excitotoxicity is a primary mechanism of brain damage in stroke, TBI, and HI, the process may be present in the majority of neurological diseases.¹⁴ Therefore, even when excitotoxicity is not the primary mechanism of pathology, neurological diseases more broadly could benefit from the development of antioxidant-nanoparticle therapies to reduce neuronal injury.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institute of General Medical Sciences (Grant #R35GM124677).

ORCID iD

Elizabeth Nance  <https://orcid.org/0000-0001-7167-7068>

References

1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation* 2017; 135: e146–e603.
2. Kurinczuk JJ, White-Koning M and Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. *Early Hum Dev* 2010; 86: 329–338.
3. Peterson AB, Xu L, Daugherty J, et al. Surveillance report of traumatic brain injury-related emergency department visits, hospitalizations, and deaths, United States, 2014. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2019.
4. Eunson P. The long-term health, social, and financial burden of hypoxic-ischaemic encephalopathy. *Dev Med Child Neurol* 2015; 57(Suppl 3): 48–50.
5. Coronado V, McGuire L, Faul M, et al. The epidemiology and prevention of TBI. In: *Brain Injury Medicine*. New York, NY: Demos, 2012: pp. 45–56.
6. Fujikawa DG. The role of excitotoxic programmed necrosis in acute brain injury. *Comput Struct Biotechnol J* 2015; 13: 212–221.
7. Dantzer R and Walker AK. Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression? *J Neural Transm* 2014; 121: 925–932.
8. Curtis C, Zhang M, Liao R, et al. Systems-level thinking for nanoparticle-mediated therapeutic delivery to neurological diseases. *Wiley Interdiscip Rev Nanomed Nanobiotechnol* 2017; 9: e1422.
9. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. *J Nutr* 2000; 130: 1007S–1015S.
10. Südhof TC. Calcium control of neurotransmitter release. *Cold Spring Harb Perspect Biol* 2012; 4: a011353.
11. Mahmoud S, Gharagozloo M, Simard C, et al. Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. *Cells* 2019; 8: 184.
12. Wang Y and Qin Z-h. Molecular and cellular mechanisms of excitotoxic neuronal death. *Apoptosis* 2010; 15: 1382–1402.
13. Girouard H, Wang G, Gallo EF, et al. NMDA receptor activation increases free radical production through nitric oxide and NOX2. *J Neurosci* 2009; 29: 2545–2552.

14. Lewerenz J and Maher P. Chronic glutamate toxicity in neurodegenerative diseases—What is the evidence? *Front Neurosci* 2015; 9: 469.
15. Swanson RA, Farrell K and Simon RP. Acidosis causes failure of astrocyte glutamate uptake during hypoxia. *J Cereb Blood Flow Metab* 1995; 15: 417–424.
16. Veenith T, Goon SS and Burnstein RM. Molecular mechanisms of traumatic brain injury: the missing link in management. *World J Emerg Surg* 2009; 4: 7.
17. Kaur P and Sharma S. Recent advances in pathophysiology of traumatic brain injury. *Curr Neuropharmacol* 2018; 16: 1224–1238.
18. Fellman V and Raivio KO. Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. *Pediatr Res* 1997; 41: 599–606.
19. Dong X-X, Wang Y and Qin Z-H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. *Acta Pharmacol Sin* 2009; 30: 379–387.
20. Hackett JT and Ueda T. Glutamate release. *Neurochem Res* 2015; 40: 2443–2460.
21. Leaw B, Nair S, Lim R, et al. Mitochondria, bioenergetics and excitotoxicity: new therapeutic targets in perinatal brain injury. *Front Cell Neurosci* 2017; 11: 199.
22. Brookes PS, Yoon Y, Robotham JL, et al. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. *Am J Physiol Cell Physiol* 2004; 287: C817–C833.
23. Dikalov S, Nazarewicz R, Panov A, et al. Crosstalk between mitochondrial ROS and NADPH oxidases in cardiovascular and degenerative diseases: application of mitochondria-targeted antioxidants. *Free Radic Biol Med* 2011; 51: S85–S86.
24. Nazarewicz RR, Dikalova AE, Bikineyeva A, et al. Nox2 as a potential target of mitochondrial superoxide and its role in endothelial oxidative stress. *Am J Physiol Heart Circ Physiol* 2013; 305: H1131–H1140.
25. Joseph LC, Barca E, Subramanyam P, et al. Inhibition of NADPH oxidase 2 (NOX2) prevents oxidative stress and mitochondrial abnormalities caused by saturated fat in cardiomyocytes. *PLoS One* 2016; 11(1): e0145750.
26. Silva GB and Garvin JL. Rac1 mediates NaCl-induced superoxide generation in the thick ascending limb. *Am J Physiol Renal Physiol* 2010; 298: F421–F425.
27. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J Clin Invest* 2003; 111: 1201–1209.
28. Alper G, Girgin FK, Ozgönül M, et al. MAO inhibitors and oxidant stress in aging brain tissue. *Eur Neuropsychopharmacol* 1999; 9: 247–252.
29. Atlante A, Gagliardi S, Minervini G, et al. Glutamate neurotoxicity in rat cerebellar granule cells: a major role for xanthine oxidase in oxygen radical formation. *J Neurochem* 1997; 68: 2038–2045.
30. Wu M-Y, Yiang G-T, Liao W-T, et al. Current mechanistic concepts in ischemia and reperfusion injury. *Cell Physiol Biochem* 2018; 46: 1650–1667.
31. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. *Am J Physiol* 1996; 271: C1424–C1437.
32. Kahraman S, Siegel A, Polster BM, et al. Permeability transition pore-dependent and PARP-mediated depletion of neuronal pyridine nucleotides during anoxia and glucose deprivation. *J Bioenerg Biomembr* 2015; 47: 53–61.
33. Adam-Vizi V and Starkov AA. Calcium and mitochondrial reactive oxygen species generation: how to read the facts. *J Alzheimers Dis* 2010; 20(Suppl 2): S413–S426.
34. Kowaltowski AJ, Castilho RF and Vercesi AE. Mitochondrial permeability transition and oxidative stress. *FEBS Lett* 2001; 495: 12–15.
35. Morciano G, Giorgi C, Bonora M, et al. Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury. *J Mol Cell Cardiol* 2015; 78: 142–153.
36. Qin YY, Li M, Feng X, et al. Combined NADPH and the NOX inhibitor apocynin provides greater anti-inflammatory and neuroprotective effects in a mouse model of stroke. *Free Radic Biol Med* 2017; 104: 333–345.
37. Duchen MR. Mitochondria and calcium: from cell signalling to cell death. *J Physiol* 2000; 529(Pt 1): 57–68.
38. Zorov DB, Juhaszova M and Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. *Physiol Rev* 2014; 94: 909–950.
39. Mander PK, Jekabsone A and Brown GC. Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase. *J Immunol* 2006; 176: 1046–1052.
40. Veal E and Day A. *Hydrogen peroxide as a signaling molecule*. New Rochelle, NY: Mary Ann Liebert, Inc, 2011.
41. Joseph A, Wood T, Chen C-C, et al. Curcumin-loaded polymeric nanoparticles for neuroprotection in neonatal rats with hypoxic-ischemic encephalopathy. *Nano Res* 2018; 11: 5670–5688.
42. Haroon E, Chen X, Li Z, et al. Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. *Transl Psychiatry* 2018; 8: 1–11.
43. McGeer PL and McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. *Parkinsonism Relat Disord* 2004; 10: S3–S7.
44. Ceulemans A-G, Zgavc T, Kooijman R, et al. The dual role of the neuroinflammatory response after ischemic stroke: modulatory effects of hypothermia. *J Neuroinflamm* 2010; 7: 74.
45. Liu F and McCullough LD. Inflammatory responses in hypoxic ischemic encephalopathy. *Acta Pharmacol Sin* 2013; 34: 1121–1130.
46. Kumar A and Loane DJ. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. *Brain Behav Immun* 2012; 26: 1191–1201.
47. Zou H, Brayer SW, Hurwitz M, et al. Neuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injury. *Neurorehabil Neural Repair* 2013; 27: 878–888.

48. Shetty AK. Prospects of levetiracetam as a neuroprotective drug against status epilepticus, traumatic brain injury, and stroke. *Front Neurol* 2013; 4: 172.
49. Ikonomidou C and Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? *Lancet Neurol* 2002; 1: 383–386.
50. Lee SG, Su ZZ, Emdad L, et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. *J Biol Chem* 2008; 283: 13116–13123.
51. Lin CL, Kong Q, Cuny GD, et al. Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases. *Future Med Chem* 2012; 4: 1689–1700.
52. Vermeij JD, Westendorp WF, Roos YB, et al. Preventive ceftriaxone in patients with stroke treated with intravenous thrombolysis: post hoc analysis of the preventive antibiotics in stroke study. *Cerebrovasc Dis* 2016; 42: 361–369.
53. Goodrich GS, Kabakov AY, Hameed MQ, et al. Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat. *J Neurotrauma* 2013; 30: 1434–1441.
54. Cook DJ, Teves L and Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. *Nature* 2012; 483: 213–217.
55. Sun HS, Doucette TA, Liu Y, et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. *Stroke* 2008; 39: 2544–2553.
56. Xu B, Xiao AJ, Chen W, et al. Neuroprotective effects of a PSD-95 inhibitor in neonatal hypoxic-ischemic brain injury. *Mol Neurobiol* 2016; 53: 5962–5970.
57. Sup SJ, Green BG and Grant SK. 2-Iminobiotin is an inhibitor of nitric oxide synthases. *Biochem Biophys Res Commun* 1994; 204: 962–968.
58. Bjorkman ST, Ireland Z, Fan X, et al. Short-term dose-response characteristics of 2-iminobiotin immediately post-insult in the neonatal piglet after hypoxia–ischemia. *Stroke* 2013; 44: 809–811.
59. Leufkens PW. 2-iminobiotin formulations and uses thereof. Google Patents, 2015.
60. Vitecek J, Lojek A, Valacchi G, et al. Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges. *Mediators Inflamm* 2012; 2012: 318087.
61. Taheraghdam AA, Sharifipour E, Pashapour A, et al. Allopurinol as a preventive contrivance after acute ischemic stroke in patients with a high level of serum uric acid: a randomized, controlled trial. *Med Princ Pract* 2014; 23: 134–139.
62. Rodriguez-Fanjul J, Duran Fernandez-Feijoo C, Lopez-Abad M, et al. Neuroprotection with hypothermia and allopurinol in an animal model of hypoxic-ischemic injury: Is it a gender question? *PLoS One* 2017; 12: e0184643.
63. Choi BY, Jang BG, Kim JH, et al. Prevention of traumatic brain injury-induced neuronal death by inhibition of NADPH oxidase activation. *Brain Res* 2012; 1481: 49–58.
64. Tang XN, Cairns B, Cairns N, et al. Apocynin improves outcome in experimental stroke with a narrow dose range. *Neuroscience* 2008; 154: 556–562.
65. Ainsley Dean PJ, Arikan G, Opitz B, et al. Potential for use of creatine supplementation following mild traumatic brain injury. *Concussion* 2017; 2: CNC34.
66. Lopez-Viata J, Mandal S, Delgado AV, et al. Electrophoretic characterization of gold nanoparticles functionalized with human serum albumin (HSA) and creatine. *J Colloid Interface Sci* 2009; 332: 215–223.
67. Dolan E, Gualano B and Rawson ES. Beyond muscle: the effects of creatine supplementation on brain creatine, cognitive processing, and traumatic brain injury. *Eur J Sport Sci* 2019; 19: 1–14.
68. Won SJ, Choi BY, Yoo BH, et al. Prevention of traumatic brain injury-induced neuron death by intranasal delivery of nicotinamide adenine dinucleotide. *J Neurotrauma* 2012; 29: 1401–1409.
69. Elizabeth Nance MM. Nanoparticles for biomedical applications. In: Chung EJ, Leon L and Rinaldi C (eds) *Chapter 7—Challenges and barriers*. Amsterdam: Elsevier, 2019, pp. 89–107.
70. Frohlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. *Int J Nanomedicine* 2012; 7: 5577–5591.
71. Li SD and Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. *Biochim Biophys Acta* 2009; 1788: 2259–2266.
72. Dziubla TD, Karim A and Muzykantov VR. Polymer nanocarriers protecting active enzyme cargo against proteolysis. *J Control Release* 2005; 102: 427–439.
73. Eijsink VG, Gaseidnes S, Borchert TV, et al. Directed evolution of enzyme stability. *Biomol Eng* 2005; 22: 21–30.
74. Lahari C, Jasti LS, Fadnavis NW, et al. Adsorption induced enzyme denaturation: the role of polymer hydrophobicity in adsorption and denaturation of alpha-chymotrypsin on allyl glycidyl ether (AGE)-ethylene glycol dimethacrylate (EGDM) copolymers. *Langmuir* 2010; 26: 1096–1106.
75. Nance E, Timbie K, Miller GW, et al. Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound. *J Control Release* 2014; 189: 123–132.
76. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. *NeuroRx* 2005; 2: 3–14.
77. Chodobski A, Zink BJ and Szmydynger-Chodobska J. Blood-brain barrier pathophysiology in traumatic brain injury. *Transl Stroke Res* 2011; 2: 492–516.
78. Jiang X, Andjelkovic AV, Zhu L, et al. Blood-brain barrier dysfunction and recovery after ischemic stroke. *Prog Neurobiol* 2018; 163–164: 144–171.
79. Moretti R, Pansiot J, Bettati D, et al. Blood-brain barrier dysfunction in disorders of the developing brain. *Front Neurosci* 2015; 9: 40.
80. Sivandzade F, Alqahtani F and Cucullo L. Traumatic brain injury and blood–brain barrier (BBB): underlying

- pathophysiological mechanisms and the influence of cigarette smoking as a premorbid condition. *Int J Mol Sci* 2020; 21: 2721.
81. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. *Adv Drug Deliv Rev* 1999; 36: 179–194.
 82. Strazielle N and Gherzi-Egea JF. Efflux transporters in blood-brain interfaces of the developing brain. *Front Neurosci* 2015; 9: 21.
 83. Kreuter J, Shamenkov D, Petrov V, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. *J Drug Target* 2002; 10: 317–325.
 84. Blanco E, Shen H and Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol* 2015; 33: 941–951.
 85. Nowak M, Brown TD, Graham A, et al. Size, shape, and flexibility influence nanoparticle transport across brain endothelium under flow. *Bioeng Transl Med* 2019; 5: e10153.
 86. Yellepeddi VK, Joseph A and Nance E. Pharmacokinetics of nanotechnology-based formulations in pediatric populations. *Adv Drug Deliv Rev* 2019; 151–152: 44–55.
 87. Zhang C, Nance EA, Mastorakos P, et al. Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. *J Control Release* 2017; 263: 112–119.
 88. Nance EA, Woodworth GF, Sailor KA, et al. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. *Sci Transl Med* 2012; 4: 149ra119.
 89. Patel PJ, Acharya NS and Acharya SR. Development and characterization of glutathione-conjugated albumin nanoparticles for improved brain delivery of hydrophilic fluorescent marker. *Drug Deliv* 2013; 20: 143–155.
 90. Mei T, Kim A, Vong LB, et al. Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment—synergistic effect of thrombolysis and antioxidant. *Biomaterials* 2019; 215: 119209.
 91. Wu W, Luo L, Wang Y, et al. Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications. *Theranostics* 2018; 8: 3038–3058.
 92. Kulkarni PS, Halder MK, Nahire RR, et al. Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. *Mol Pharm* 2014; 11: 2390–2399.
 93. Cho H, Bae J, Garripelli VK, et al. Redox-sensitive polymeric nanoparticles for drug delivery. *Chem Commun (Camb)* 2012; 48: 6043–6045.
 94. Fisher DG and Price RJ. Recent advances in the use of focused ultrasound for magnetic resonance image-guided therapeutic nanoparticle delivery to the central nervous system. *Front Pharmacol* 2019; 10: 1348.
 95. Geho DH, Jones CD, Petricoin EF, et al. Nanoparticles: potential biomarker harvesters. *Curr Opin Chem Biol* 2006; 10: 56–61.
 96. Chinen AB, Guan CM, Ferrer JR, et al. Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence. *Chem Rev* 2015; 115: 10530–10574.
 97. Reddy MK, Wu L, Kou W, et al. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. *Appl Biochem Biotechnol* 2008; 151: 565–577.
 98. Reddy MK and Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. *FASEB J* 2009; 23: 1384–1395.
 99. Yun X, Maximov VD, Yu J, et al. Nanoparticles for targeted delivery of antioxidant enzymes to the brain after cerebral ischemia and reperfusion injury. *J Cereb Blood Flow Metab* 2013; 33: 583–592.
 100. Stanimirovic DB, Markovic M, Micic DV, et al. Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion ‘oxidative stress’ in gerbil brain. *Neurochem Res* 1994; 19: 1473–1478.
 101. Imaizumi S, Woolworth V, Fishman RA, et al. Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats. *Stroke* 1990; 21: 1312–1317.
 102. Chan PH, Longar S and Fishman RA. Protective effects of liposome-entrapped superoxide dismutase on posttraumatic brain edema. *Ann Neurol* 1987; 21: 540–547.
 103. Jiang Y, Arounleut P, Rheiner S, et al. SOD1 nanozyme with reduced toxicity and MPS accumulation. *J Control Release* 2016; 231: 38–49.
 104. Manickam DS, Brynskikh AM, Kopanic JL, et al. Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury. *J Control Release* 2012; 162: 636–645.
 105. Liao R, Wood TR and Nance E. Superoxide dismutase reduces monosodium glutamate-induced injury in an organotypic whole hemisphere brain slice model of excitotoxicity. *J Biol Eng* 2020; 14: 3.
 106. Haney MJ, Zhao Y, Li S, et al. Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells. *Nanomedicine (Lond)* 2011; 6: 1215–1230.
 107. Singhal A, Morris VB, Labhasetwar V, et al. Nanoparticle-mediated catalase delivery protects human neurons from oxidative stress. *Cell Death Dis* 2013; 4: e903.
 108. Zhang C, Ling CL, Pang L, et al. Direct macromolecular drug delivery to cerebral ischemia area using neutrophil-mediated nanoparticles. *Theranostics* 2017; 7: 3260–3275.
 109. Petro M, Jaffer H, Yang J, et al. Tissue plasminogen activator followed by antioxidant-loaded nanoparticle delivery promotes activation/mobilization of progenitor cells in infarcted rat brain. *Biomaterials* 2016; 81: 169–180.
 110. Lutton EM, Razmpour R, Andrews AM, et al. Acute administration of catalase targeted to ICAM-1 attenuates neuropathology in experimental traumatic brain injury. *Sci Rep* 2017; 7: 3846.
 111. Islam MN, Zhang M and Adhikari B. The inactivation of enzymes by ultrasound—a review of potential mechanisms. *Food Rev Int* 2014; 30: 1–21.

112. van de Weert M, Hennink WE and Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. *Pharm Res* 2000; 17: 1159–1167.
113. Yu M, Wu J, Shi J, et al. Nanotechnology for protein delivery: overview and perspectives. *J Control Release* 2016; 240: 24–37.
114. Liao R, Pon J, Chungyoum M, et al. Enzymatic protection and biocompatibility screening of enzyme-loaded polymeric nanoparticles for neurotherapeutic applications. *Biomaterials* 2020; 257: 120238.
115. Valgimigli L, Baschieri A and Amorati R. Antioxidant activity of nanomaterials. *J Mater Chem B* 2018; 6: 2036–2051.
116. Takamiya M, Miyamoto Y, Yamashita T, et al. Strong neuroprotection with a novel platinum nanoparticle against ischemic stroke- and tissue plasminogen activator-related brain damages in mice. *Neuroscience* 2012; 221: 47–55.
117. Rzigalinski BA, Carfagna CS and Ehrlich M. Cerium oxide nanoparticles in neuroprotection and considerations for efficacy and safety. *Wiley Interdiscip Rev Nanomed Nanobiotecnol* 2017; 9. DOI: 10.1002/wnan.1444.
118. Kim CK, Kim T, Choi IY, et al. Ceria nanoparticles that can protect against ischemic stroke. *Angew Chem Int Ed Engl* 2012; 51: 11039–11043.
119. He L, Huang G, Liu H, et al. Highly bioactive zeolitic imidazolate framework-8-capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke. *Sci Adv* 2020; 6: eaay9751.
120. Estevez A and Erlichman J. Cerium oxide nanoparticles for the treatment of neurological oxidative stress diseases. In: Andreescu S and Hepel M (eds) *Oxidative stress: diagnostics, prevention, and therapy*. Washington, DC: ACS Publications, 2011, pp. 255–288.
121. Singh N, Cohen CA and Rzigalinski BA. Treatment of neurodegenerative disorders with radical nanomedicine. *Ann NY Acad Sci* 2007; 1122: 219–230.
122. Schubert D, Dargusch R, Raitano J, et al. Cerium and yttrium oxide nanoparticles are neuroprotective. *Biochem Biophys Res Commun* 2006; 342: 86–91.
123. Zha YY, Yang B, Tang ML, et al. Concentration-dependent effects of fullerene on cultured hippocampal neuron viability. *Int J Nanomedicine* 2012; 7: 3099–3109.
124. Lin AM, Fang SF, Lin SZ, et al. Local carboxyfullerene protects cortical infarction in rat brain. *Neurosci Res* 2002; 43: 317–321.
125. Djordjevic A, Srdjenovic B, Seke M, et al. Review of synthesis and antioxidant potential of fullerene nanoparticles. *J Nanomater* 2015; 2015. DOI: 10.1155/2015/567073.
126. Kim YO, Kim HJ and Kim SK. Neuroprotective effects of hydroxyfullerene in rats subjected to global cerebral ischemia. *Mol Cell Toxicol* 2008; 4(3): 218–223.
127. Vani JR, Mohammadi MT, Foroshani MS, et al. Polyhydroxylated fullerene nanoparticles attenuate brain infarction and oxidative stress in rat model of ischemic stroke. *EXCLI J* 2016; 15: 378–390.
128. Samuel EL, Marcano DC, Berka V, et al. Highly efficient conversion of superoxide to oxygen using hydrophilic carbon clusters. *Proc Natl Acad Sci USA* 2015; 112: 2343–2348.
129. Huq R, Samuel EL, Sikkema WK, et al. Preferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation. *Sci Rep* 2016; 6: 33808.
130. Nilewski LG, Sikkema WK, Kent TA, et al. Carbon nanoparticles and oxidative stress: Could an injection stop brain damage in minutes? *Nanomedicine (Lond)* 2015; 10: 1677–1679.
131. Fabian RH, Derry PJ, Rea HC, et al. Efficacy of novel carbon nanoparticle antioxidant therapy in a severe model of reversible middle cerebral artery stroke in acutely hyperglycemic rats. *Front Neurol* 2018; 9: 199.
132. Bitner BR, Marcano DC, Berlin JM, et al. Antioxidant carbon particles improve cerebrovascular dysfunction following traumatic brain injury. *ACS Nano* 2012; 6: 8007–8014.
133. Carlander U, Moto TP, Desalegn AA, et al. Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics. *Int J Nanomedicine* 2018; 13: 2631–2646.
134. Hendrickson O, Zherdev A, Gmshinskii I, et al. Fullerenes: in vivo studies of biodistribution, toxicity, and biological action. *Nanotechnol Russ* 2014; 9: 601–617.
135. Bond WS and Rex TS. Evidence that erythropoietin modulates neuroinflammation through differential action on neurons, astrocytes, and microglia. *Front Immunol* 2014; 5: 523.
136. Katavetin P, Tungsanga K, Eiam-Ong S, et al. Antioxidative effects of erythropoietin. *Kidney Int Suppl* 2007; 72(Suppl 107): S10–S15. DOI: 10.1038/sj.ki.5002482.
137. Bailey DM, Lundby C, Berg RM, et al. On the antioxidant properties of erythropoietin and its association with the oxidative-nitrosative stress response to hypoxia in humans. *Acta Physiol (Oxf)* 2014; 212: 175–187.
138. Chen H, Spagnoli F, Burris M, et al. Nanoerythropoietin is 10-times more effective than regular erythropoietin in neuroprotection in a neonatal rat model of hypoxia and ischemia. *Stroke* 2012; 43: 884–887.
139. Dai W, Wang H, Fang J, et al. Curcumin provides neuroprotection in model of traumatic brain injury via the Nrf2-ARE signaling pathway. *Brain Res Bull* 2018; 140: 65–71.
140. Miao Y, Zhao S, Gao Y, et al. Curcumin pretreatment attenuates inflammation and mitochondrial dysfunction in experimental stroke: the possible role of Sirt1 signaling. *Brain Res Bull* 2016; 121: 9–15.
141. Liu Z, Ran Y, Huang S, et al. Curcumin protects against ischemic stroke by titrating microglia/macrophage polarization. *Front Aging Neurosci* 2017; 9: 233.
142. Kakkar V, Muppu SK, Chopra K, et al. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. *Eur J Pharm Biopharm* 2013; 85: 339–345.
143. Ahmad N, Umar S, Ashafaq M, et al. A comparative study of PNIPAM nanoparticles of curcumin, demethoxycurcumin,

- and bisdemethoxycurcumin and their effects on oxidative stress markers in experimental stroke. *Protoplasma* 2013; 250: 1327–1338.
144. Liu Y, Ai K, Ji X, et al. Comprehensive insights into the multi-antioxidative mechanisms of melanin nanoparticles and their application to protect brain from injury in ischemic stroke. *J Am Chem Soc* 2017; 139: 856–862.
145. Bavarsad Shahripour R, Harrigan MR and Alexandrov AV. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. *Brain Behav* 2014; 4: 108–122.
146. Nance E, Porambo M, Zhang F, et al. Systemic dendrimer-drug treatment of ischemia-induced neonatal white matter injury. *J Control Release* 2015; 214: 112–120.
147. Cunha RA. Neuroprotection by adenosine in the brain: from A(1) receptor activation to A(2A) receptor blockade. *Purinergic Signal* 2005; 1: 111–134.
148. Rouquette M, Lepetre-Mouelhi S, Dufrancais O, et al. Squalene-adenosine nanoparticles: ligands of adenosine receptors or adenosine prodrug? *J Pharmacol Exp Ther* 2019; 369: 144–151.
149. Gaudin A, Yemisci M, Eroglu H, et al. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. *Nat Nanotechnol* 2014; 9: 1054–1062.
150. Lu X, Dong J, Zheng D, et al. Reperfusion combined with intraarterial administration of resveratrol-loaded nanoparticles improved cerebral ischemia–reperfusion injury in rats. *Nanomedicine* 2020; 28: 102208.
151. Kumar PP, Nainita MK, Tarun AS, et al. Cerebroprotective potential of hesperidin nanoparticles against bilateral common carotid artery occlusion reperfusion injury in rats and in silico approaches. *Neurotox Res* 2020; 37: 264–274.
152. Kusaka T, Matsuura S, Fujikawa Y, et al. Relationship between cerebral interstitial levels of amino acids and phosphorylation potential during secondary energy failure in hypoxic-ischemic newborn piglets. *Pediatr Res* 2004; 55: 273–279.
153. Dietrich WD and Bramlett HM. Therapeutic hypothermia and targeted temperature management for traumatic brain injury: experimental and clinical experience. *Brain Circ* 2017; 3: 186–198.
154. Wassink G, Davidson JO, Dhillon SK, et al. Therapeutic hypothermia in neonatal hypoxic-ischemic encephalopathy. *Curr Neurol Neurosci Rep* 2019; 19: 2.
155. Kurisu K and Yenari MA. Therapeutic hypothermia for ischemic stroke; pathophysiology and future promise. *Neuropharmacology* 2018; 134: 302–309.
156. Wassink G, Davidson JO, Lear CA, et al. A working model for hypothermic neuroprotection. *J Physiol* 2018; 596: 5641–5654.
157. Chakkarapani E, Dingley J, Liu X, et al. Xenon enhances hypothermic neuroprotection in asphyxiated newborn pigs. *Ann Neurol* 2010; 68: 330–341.
158. Hobbs C, Thoresen M, Tucker A, et al. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. *Stroke* 2008; 39: 1307–1313.
159. Thoresen M, Hobbs CE, Wood T, et al. Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia–ischemia. *J Cereb Blood Flow Metab* 2009; 29: 707–714.
160. Azzopardi D, Robertson NJ, Bainbridge A, et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. *Lancet Neurol* 2016; 15: 145–153.
161. Thoresen M, Satas S, Puka-Sundvall M, et al. Post-hypoxic hypothermia reduces cerebrocortical release of NO and excitotoxins. *Neuroreport* 1997; 8: 3359–3362.
162. Hassell KJ, Ezzati M, Alonso-Alconada D, et al. New horizons for newborn brain protection: enhancing endogenous neuroprotection. *Arch Dis Child Fetal Neonatal Ed* 2015; 100: F541–F552.
163. Faden AI and Loane DJ. Chronic neurodegeneration after traumatic brain injury: Alzheimer disease, chronic traumatic encephalopathy, or persistent neuroinflammation? *Neurotherapeutics* 2015; 12: 143–150.
164. DeBow SB, Clark DL, MacLellan CL, et al. Incomplete assessment of experimental cytoprotectants in rodent ischemia studies. *Can J Neurol Sci* 2003; 30: 368–374.
165. Galinsky R, Dean JM, Lear CA, et al. In the era of therapeutic hypothermia, how well do studies of perinatal neuroprotection control temperature? *Dev Neurosci* 2017; 39: 7–22.
166. Wood T, Hobbs C, Falck M, et al. Rectal temperature in the first five hours after hypoxia-ischaemia critically affects neuropathological outcomes in neonatal rats. *Pediatr Res* 2017; 83: 536–544.
167. Liedtke WB. Deconstructing mammalian thermoregulation. *Proc Natl Acad Sci USA* 2017; 114: 1765–1767.
168. Morrison SF and Nakamura K. Central neural pathways for thermoregulation. *Front Biosci (Landmark Ed)* 2011; 16: 74–104.
169. Nurse S and Corbett D. Neuroprotection after several days of mild, drug-induced hypothermia. *J Cereb Blood Flow Metab* 1996; 16: 474–480.
170. Rubiano AM, Sanchez AI, Estebanez G, et al. The effect of admission spontaneous hypothermia on patients with severe traumatic brain injury. *Injury* 2013; 44: 1219–1225.
171. Konstantinidis A, Inaba K, Dubose J, et al. The impact of nontherapeutic hypothermia on outcomes after severe traumatic brain injury. *J Trauma* 2011; 71: 1627–1631.
172. Lascarrou JB, Merdji H, Le Gouge A, et al. Targeted temperature management for cardiac arrest with nonshockable rhythm. *N Engl J Med* 2019; 381: 2327–2337.
173. Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. *N Engl J Med* 2013; 369: 2197–2206.

174. Wood T, Osredkar D, Puchades M, et al. Treatment temperature and insult severity influence the neuroprotective effects of therapeutic hypothermia. *Sci Rep* 2016; 6: 23430.
175. O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. *Ann Neurol* 2006; 59: 467–477.
176. Gebhardt K, Guyette FX, Doshi AA, et al. Prevalence and effect of fever on outcome following resuscitation from cardiac arrest. *Resuscitation* 2013; 84: 1062–1067.
177. Laptook AR, McDonald SA, Shankaran S, et al. Elevated temperature and 6- to 7-year outcome of neonatal encephalopathy. *Ann Neurol* 2013; 73: 520–528.
178. Wood T and Nance E. Disease-directed engineering for physiology-driven treatment interventions in neurological disorders. *APL Bioeng* 2019; 3: 040901.
179. Jayaraj RL, Azimullah S, Beiram R, et al. Neuroinflammation: friend and foe for ischemic stroke. *J Neuroinflammation* 2019; 16: 142.
180. Buetler TM, Krauskopf A and Ruegg UT. Role of superoxide as a signaling molecule. *News Physiol Sci* 2004; 19: 120–123.
181. Wu QJ and Tymianski M. Targeting NMDA receptors in stroke: new hope in neuroprotection. *Mol Brain* 2018; 11: 15.